Onconostic Technologies/3N Diagnostics (OT/3NDx) is multi-sector healthcare platform company based on FOXC1, the master gene regulator driving metastasis in breast and other cancers. The company has developed 3 main business opportunities leading to sales revenues, strategic licensing, and potential exits: DIAGNOSTIC: Early detection of aggressive metastatic cancer. First product Veresca®FOXC1 test has regulatory approval in EU and is in use in hospitals OUS. THERAPEUTICS: Development of novel drugs preventing metastasis, complementary diagnostics for FDA-approved drugs via strategic licensing with Pharma. DATA MANAGEMENT: Proprietary algorithms/databases for oncology management via strategic licensing with Big Data. OT is based in the US. Its sister company 3NDx, is based in Northern Ireland to carry out manufacturing, marketing, regulatory (CE Mark), and accelerate worldwide product introduction.